This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Rhesus macaque VEGF R1 / Flt-1 Protein, Mouse IgG2a Fc Tag, low endotoxin
catalog :
VE1-R5257
quantity :
1 mg, 100 ug
price :
2310 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
VE1-R5257
product name :
Rhesus macaque VEGF R1 / Flt-1 Protein, Mouse IgG2a Fc Tag, low endotoxin
quantity :
1 mg, 100 ug
price :
2310 USD, 350 USD
quantity & price :
$350/100ug,$2310/1mg (200ug × 5)
target :
VEGF R1
host species :
Rhesus macaque
By Tag :
Mouse IgG Fc Tag
Research :
For Research Use Only
Source :
Rhesus macaque VEGF R1, Mouse IgG2a Fc Tag, low endotoxin (VE1-R5257) is expressed from human 293 cells (HEK293). It contains AA Ser 27 - Asn 756 (Accession # F7FAY2-1).
Endotoxin :
Less than 0.1 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Rhesus macaque VEGF R1, Mouse IgG2a Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Vascular endothelial growth factor receptor 1 (VEGFR1) is also known as Fms-like tyrosine kinase 1 (FLT-1), Tyrosine-protein kinase receptor FLT, is a single-pass type I membrane protein and secreted protein which belongs to the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR1 is detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues and specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR1 acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR1 may play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood.
References :
(1) Shibuya M., et al., 1990, Oncogene 5:519-524.
(2) Kendall R.L., et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:10705-10709.
(3) Seetharam L., et al., 1995, Oncogene 10:135-147.
(4) Barleon B., et al., 1996, Blood 87:3336-3343.
(5) Grunewald F.S., et al., 2010, Biochim. Biophys. Acta 1804:567-580.
(6) Iyer S., et al., 2010, J. Biol. Chem. 285:23779-23789.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments